EXEL News and Press, Exelixis Inc. From 07/19/22

Exelixis ( NASDAQ: EXEL ) is accusing MSN Pharmacueticals of patent infringement over its Abbreviated New Drug Application to market a generic of Cabometyx (cabozantinib). The lawsuit was filed Monday in a Delaware federal court. Exelixis is assert infringement of ...

As of June 30, 2022, AAII’s Oberweis Octagon screening model has an annual gain since inception (1998) of 11.4%. The AAII Oberweis Octagon strategy seeks rapidly growing small- to mid-size companies trading at attractive prices. The Oberweis Octagon screen seeks to identify...

Exelixis ( NASDAQ: EXEL ) on Monday said its phase 3 trial evaluating its cabozantinib medicine in combination with two other cancer drugs for the treatment of kidney cancer met its main goal. The late-stage trial, called COSMIC-313, is investigating EXEL's cabozantini...

– Exelixis intends to discuss the results with the U.S. FDA to determine next steps toward a potential regulatory submission – – Trial to continue until the next analysis of the secondary endpoint of overall survival – Exelixis, ...

Exelixis ( NASDAQ: EXEL ) signed a licensing agreement with Poland-based Ryvu Therapeutics to develop novel targeted cancer therapies. Under the terms of the agreement, Exelixis will pay Ryvu $3M upfront in exchange for certain rights to Ryvu's STING agonist small...

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential – Exelixi...

-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand begi...

The stock market might not look so attractive right now, with the S&P 500 down 18% so far this year. But even good businesses with strong fundamentals experience ups and downs. It doesn't mean these stocks should be abandoned. History tells us a distressed market creates investment ...

BMO Capital Markets has initiated the coverage of oncology-focused biotech Exelixis (NASDAQ:EXEL) with an Outperform recommendation arguing that the company shares are trading below a worst-case scenario implied for a potential entry of generics. The price target of $28 per share implies a pr...

Exelixis (NASDAQ:EXEL) said it began a phase 3 trial of XL092 in combination with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Tecentriq (atezolizumab) versus Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Stivarga (regorafenib) in patients with metastatic colorectal cancer which is not microsatellite insta...